A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: Design and rationale of the RADAR Phase IIb trial

(2011) Thomas J. Povsic et al.   AMERICAN HEART JOURNAL

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

(2011) Ph. Gabriel Steg et al.   EUROPEAN HEART JOURNAL

Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy

(2011) T. J. Povsic et al.   EUROPEAN HEART JOURNAL

Radial Artery Access as a Predictor of Increased Radiation Exposure During a Diagnostic Cardiac Catheterization Procedure

(2011) Mathew Mercuri et al.   JACC-Cardiovascular Interventions

Dose Selection for a Direct and Selective Factor IXa Inhibitor and its Complementary Reversal Agent: Translating Pharmacokinetic and Pharmacodynamic Properties of the REG1 System to Clinical Trial Design

(2011) T. J. Povsic et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial

(2011) Sanjit S Jolly et al.   LANCET

Meta-analysis of randomized trials on the efficacy of vascular closure devices after diagnostic angiography and angioplasty

(2010) Fausto Biancari et al.   AMERICAN HEART JOURNAL

First Clinical Application of an Actively Reversible Direct Factor IXa Inhibitor as an Anticoagulation Strategy in Patients Undergoing Percutaneous Coronary Intervention

(2010) Mauricio G. Cohen et al.   CIRCULATION

Nucleic acid aptamers as antithrombotic agents: Opportunities in extracellular therapeutics

(2010) Thomas Povsic et al.   THROMBOSIS AND HAEMOSTASIS

Translating Nucleic Acid Aptamers to Antithrombotic Drugs in Cardiovascular Medicine

(2010) Thomas J. Povsic et al.   Journal of Cardiovascular Translational Research

Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial

(2009) Marc S Sabatine et al.   LANCET

Impact of anticoagulation regimens on sheath management and bleeding in patients undergoing elective percutaneous coronary intervention in the STEEPLE trial

(2008) Richard Gallo et al.   CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS

Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients With Stable Coronary Artery Disease

(2008) Mark Y. Chan et al.   CIRCULATION

Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study

(2008) B. I. ERIKSSON et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Relationship between markers of activated coagulation, their correlation with inflammation, and association with coronary heart disease (NPHSII)

(2008) G. J. MILLER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor

(2008) M. Y. CHAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Bivalirudin during Primary PCI in Acute Myocardial Infarction

(2008) Gregg W. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE